ALBANY, N.Y., May 2, 2017 /PRNewswire/
-- AMRI (NASDAQ: AMRI) today announced it received a
5-year federal contract award from the National Center for
Advancing Translational Sciences (NCATS), part of the National
Institutes of Health (NIH), for drug substance development and
manufacturing services. The NCATS award will support the Division
of Pre-Clinical Innovation's (DPI) drug development programs
by providing drug substance development and manufacturing services
related to the synthesis and analysis of small molecules.
The goal of the DPI is to advance collaborative research
projects across pre-clinical phases of the translational science
spectrum. Through this contract AMRI will support the DPI
scientists to advance early stage NCATS drug discovery projects
from candidate nomination to clinical trials, by providing services
related to process development, analytical development and GMP
manufacture of small molecule drug candidates to support clinical
trials.
"Our mission is to provide our customers a complete suite of
services across the drug discovery, development and manufacturing
continuum for the advancement of much needed medicines to improve
patient outcomes," said Christopher
Conway, senior vice president of Drug Discovery, Development
and Analytical Services (DDS). "AMRI is confident that our track
record of success in advancing programs from pre-clinical to
commercial launch will support NIH's mission to translate
scientific knowledge into effective therapies."
About AMRI
AMRI is a global contract
research and manufacturing organization that has been working with
the life sciences industry to improve patient outcomes and the
quality of life for more than two decades. With locations in
North America, Europe and Asia, our key business segments include
Discovery and Development Services (DDS), Active Pharmaceutical
Ingredients (API), Drug Product (DP), and Fine Chemicals. For more
information about AMRI, please visit our website at
www.amriglobal.com or follow us on Twitter (@amriglobal).
AMRI Forward-Looking Statement
This press release includes forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as "will," "may," "intends," "anticipate," "plan,"
"enables," "potentially," "expects," and similar expressions are
intended to identify forward-looking statements, although not all
forward-looking statements contain these identifying words.
These statements include, but are not limited to: statements
regarding the goals of the DPI, AMRI's expected future performance
pursuant to the NIH contract award and the likelihood that the NIH
contract award will ultimately result in approved and effective
therapies. All such statements are subject to certain risks
and uncertainties, many of which are difficult to predict and
generally beyond AMRI's control, that could cause actual results to
differ materially from those expressed in, or implied or projected
by, the forward-looking information and statements. Such
risks include, but are not limited to: whether AMRI will
successfully perform under the NIH contract award; the continuation
of the DPI drug development programs under which AMRI is providing
services; whether AMRI's services will ultimately result in
approved and effective therapies; as well as those risks that are
discussed in AMRI's Annual Report on Form 10-K for the fiscal year
ended December 31, 2016 as filed with
the U.S. Securities and Exchange Commission on March 16, 2017 and other subsequent filings with
the U.S. Securities and Exchange Commission. Readers are
cautioned not to place undue reliance on these forward-looking
statements that speak only as of the date hereof, and AMRI does not
undertake any obligation to revise and disseminate forward-looking
statements to reflect events or circumstances after the date
hereof, or to reflect the occurrence of or non-occurrence of any
events.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/amri-receives-nih-contract-award-for-drug-substance-development-and-manufacturing-services-300449215.html
SOURCE AMRI